Priming of strong, broad, and long-lived HIV type 1 p55(gag)-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques

AIDS Research and Human Retroviruses

Volumn 16, Issue 3, 2000, Pages 273-282

  Paliard, Xavier ^a   Liu, Yuan ^a   Wagner, Ralf ^b   Wolf, Hans ^b   Baenziger, Juerg ^a   Walker, Christopher M ^a,c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEIN P55;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VACCINATION; VIRUS PARTICLE;

AIDS VACCINES; ANIMALS; ANTIGEN PRESENTATION; GENE PRODUCTS, GAG; HIV-1; HUMANS; LYMPH NODES; MACACA MULATTA; PEPTIDES; PROTEIN PRECURSORS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; VACCINATION; VIRION;

EID: 0034628629     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200309368     Document Type: Article

References (52)

1. 1. Daniel M, Kirchhoff F, Czajak S, Sehgal P, and Desrosiers R: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-1941.
2. 3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). J Infect Dis 1996;173:1336-1346.
3. 3. Graham B, Keefer M, McElrath M, et al.: Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med 1996; 125:270-279.
4. 4. Keefer M, Graham B, McElrath M, et al.: Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type I candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1996;12:683-693.
5. 5. Mascola J, Snyder S, Weislow O, et al.: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996;173:340-348.
6. 6. Shibata R, Igarashi T, Haigwood N, et al.: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Med 1999;5:204-216.
7. 7. Igarashi T, Brown C, Azadegan A, et al.: Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nature Med 1999;5:211-216.
8. 8. Burton D: A vaccine for HIV type 1: The antibody perspective. Proc Natl Acad Sci USA 1997;94:10018-10023.
9. 9. Moore J and Burton D: HIV-1 neutralizing antibodies: How full is the bottle? Nature Med 1999;5:142-144.
10. 10. Ada G and Jones P: The immune response to influenza infection. Curr Top Microbiol Immunol 1986;128:1-54.
11. 11. Cannon M, Openshaw P, and Askonas B: Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 1988;168:1163-1168.
12. 12. Reusser P, Riddell S, Meyers J, and Greenberg P: Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78:1373-1380.
13. 13. Musey L, Hughes J, Schacker T, et al.: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997;337:1267-1274.
14. 14. Ogg G, Jin X, Bonhoeffer S, et al.: Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-2106.
15. + lymphocytes. Science 1999;283:857-860.
16. 16. Jassoy C and Walker B: HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. Springer Semin Immunopathol 1997;18:341-354.
17. 17. Carmichael A, Jin X, Sissons P, and Borysiewicz L: Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993;177:249-256.
18. 18. Klein M, van Baalen C, Holwerda A, et al.: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-1372.
19. 19. Harrer T, Harrer E, Kalams S, et al.: Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasi-species in a person with prolonged infection and low viral load. J Immunol 1996;156:2616-2623.
20. 20. Borrow P, Lewicki H, Wei X, et al.: Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med 1997;3:205-211.
21. 21. Brodie S, Lewinsohn D, Patterson B, et al.: In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nature Med 1999;5:34-41.
22. 22. Rowland-Jones S and McMichael A: Immune responses in HIV-exposed seronegatives: Have they repelled the virus? Curr Opin Immunol 1995;7:448-455.
23. 23. Baba T, Jeong Y, Pennick D, et al.: Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995;267:1820-1825.
24. 24. Baba T, Liska V, Khimani A, et al.: Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nature Med 1999;5:194-203.
25. 25. Ulmer J, Donnelly J, Parker S, et al.: Heterologous protection against influenza by infection of DNA encoding a viral protein. Science 1993;259:1745-1749.
26. 26. Manning W, Paliard X, Zhou S, et al.: Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J Virol 1997;71:7960-7962.
27. + T cells in vivo: A study with the nucleoprotein of the lymphocytic choriomeningitis virus. Int Immunol 1995;7:797-805.
28. 28. Caley I, Betts M, Irlbeck D, et al.: Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol 1997;71:3031-3038.
29. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature (London) 1990;344:873-875.
30. 30. National Institutes of Health: Guide for the Care and Use of Laboratory Animals. U.S. Department of Health and Human Services Publication No. 82-23. National Institutes of Health, Bethesda, MD, 1985.
31. 31. Wagner R, Deml L, Teeuwsen V, et al.: A recombinant HIV-1 virus-like particle vaccine: From concepts to a field study. Antibiot Chemother 1996;48:68-83.
32. 32. Wagner R, Deml L, Schirmbeck R, Reimann J, and Wolf H: Induction of an MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: Implications on HIV vaccine development. Behring Inst Mitt 1994;95: 23-34.
33. 33. Paliard X, Doe B, and Walker C: The T cell repertoire primed by antiviral vaccination is influenced by self-tolerance. Cell Immunol 1998;188:73-79.
34. 34. Erickson A, Houghton M, Choo Q, et al.: Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol 1993;151:4189-4199.
35. 35. Letvin N: Vaccines against human immunodeficiency virus -progress and prospects. N Engl J Med 1993;329:1400-1405.
36. 36. Laurent S, Vautherot J, Madelaine M, Le Gall G, and Rasschaert D: Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection. J Virol 1994;68:6794-6798.
37. 37. Kosukegawa A, Arisaka F, Takayama M, et al.: Purification and characterization of virus-like particles and pentamers produced by the expression of SV 40 capsid proteins in insect cells. Biochim Biophys Acta 1996;1290:37-45.
38. 38. McCarthy M, White W, Palmer-Hill F, Koenig S, and Suzich J: Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J Virol 1998;72:32-41.
39. 39. Roy P, Bishop D, LeBlois H, and Erasmus B: Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: Evidence for homologous and partial heterologous protection. Vaccine 1994;12:805-811.
40. 40. Deml L, Schirmbeck R, Reimann J, Wolf H, and Wagner R: Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology 1997;235:26-39.
41. 41. Wagner R, Deml L, Schirmbeck R, et al.: Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Virology 1996;220:128-140.
42. 42. Egan M, Pavlat W, Tartaglia J, et al.: Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, hostrange-restricted canarypox vector (ALVAC) carrying the HIV-1 MN env gene. J Infect Dis 1995;171:1623-1627.
43. 43. Perales M, Schwartz D, Fabry J, and Lieberman J: A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:27-35.
44. 44. Fleury B, Janvier G, Pialoux G, et al.: Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996;174:734-738.
45. 45. Ferrari G, Berend C, Ottinger J, et al.: Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy. Blood 1997;90:2406-2416.
46. 46. Ugen K, Boyer J, Wang B, et al.: Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV-1: Prelude to a clinical trial. Vaccine 1997;15:927-930.
47. 47. Yasutomi Y, Robinson H, Lu S, et al.: Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol 1996;70:678-681.
48. 48. Johnson R, Glickman R, Yang J, et al.: Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol 1997;71:7711-7718.
49. 49. Yasutomi Y, Koenig S, Woods R, et al.: A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J Virol 1995;69:2279-2284.
50. 50. Ahmed R and Gray D: Immunological memory and protective immunity: Understanding their relation. Science 1996;272:54-60.
51. 51. McMichael A and O'Callaghan C: A new look at T cells. J Exp Med 1998;187:1367-1371.
52. 51. Spira A, Marx P, Patterson B, et al.: Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996;183:215-225.